176 related articles for article (PubMed ID: 21559085)
1. The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse.
Marchini C; Gabrielli F; Iezzi M; Zenobi S; Montani M; Pietrella L; Kalogris C; Rossini A; Ciravolo V; Castagnoli L; Tagliabue E; Pupa SM; Musiani P; Monaci P; Menard S; Amici A
PLoS One; 2011 Apr; 6(4):e18727. PubMed ID: 21559085
[TBL] [Abstract][Full Text] [Related]
2. Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib.
Tilio M; Gambini V; Wang J; Garulli C; Kalogris C; Andreani C; Bartolacci C; Elexpuru Zabaleta M; Pietrella L; Hysi A; Iezzi M; Belletti B; Orlando F; Provinciali M; Galeazzi R; Marchini C; Amici A
Cancer Lett; 2016 Oct; 381(1):76-84. PubMed ID: 27475932
[TBL] [Abstract][Full Text] [Related]
3. Loss of the extracellular matrix glycoprotein EMILIN1 accelerates Δ16HER2-driven breast cancer initiation in mice.
Favero A; Segatto I; Capuano A; Mattevi MC; Rampioni Vinciguerra GL; Musco L; D'Andrea S; Dall'Acqua A; Gava C; Perin T; Massarut S; Marchini C; Baldassarre G; Spessotto P; Belletti B
NPJ Breast Cancer; 2024 Jan; 10(1):5. PubMed ID: 38184660
[TBL] [Abstract][Full Text] [Related]
4. Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer.
Bartolacci C; Andreani C; Curcio C; Occhipinti S; Massaccesi L; Giovarelli M; Galeazzi R; Iezzi M; Tilio M; Gambini V; Wang J; Marchini C; Amici A
Cancer Immunol Res; 2018 Dec; 6(12):1486-1498. PubMed ID: 30327365
[TBL] [Abstract][Full Text] [Related]
5. The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment.
Turpin J; Ling C; Crosby EJ; Hartman ZC; Simond AM; Chodosh LA; Rennhack JP; Andrechek ER; Ozcelik J; Hallett M; Mills GB; Cardiff RD; Gray JW; Griffith OL; Muller WJ
Oncogene; 2016 Nov; 35(47):6053-6064. PubMed ID: 27157621
[TBL] [Abstract][Full Text] [Related]
6. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
7. Stathmin Is Required for Normal Mouse Mammary Gland Development and Δ16HER2-Driven Tumorigenesis.
Segatto I; Zompit MM; Citron F; D'Andrea S; Vinciguerra GLR; Perin T; Berton S; Mungo G; Schiappacassi M; Marchini C; Amici A; Vecchione A; Baldassarre G; Belletti B
Cancer Res; 2019 Jan; 79(2):397-409. PubMed ID: 30478213
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol fuels HER2 and ERα-positive breast cancer behaving as proteasome inhibitor.
Andreani C; Bartolacci C; Wijnant K; Crinelli R; Bianchi M; Magnani M; Hysi A; Iezzi M; Amici A; Marchini C
Aging (Albany NY); 2017 Feb; 9(2):508-523. PubMed ID: 28238967
[TBL] [Abstract][Full Text] [Related]
9. MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice.
Zhou H; Chen WD; Qin X; Lee K; Liu L; Markowitz SD; Gerson SL
Oncogene; 2001 Sep; 20(42):6009-17. PubMed ID: 11593408
[TBL] [Abstract][Full Text] [Related]
10. Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors.
Romieu-Mourez R; Kim DW; Shin SM; Demicco EG; Landesman-Bollag E; Seldin DC; Cardiff RD; Sonenshein GE
Mol Cell Biol; 2003 Aug; 23(16):5738-54. PubMed ID: 12897145
[TBL] [Abstract][Full Text] [Related]
11. Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice.
Ma Z; Parris AB; Xiao Z; Howard EW; Kosanke SD; Feng X; Yang X
J Exp Clin Cancer Res; 2017 Jan; 36(1):6. PubMed ID: 28061785
[TBL] [Abstract][Full Text] [Related]
12. A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis.
Dearth RK; Kuiatse I; Wang YF; Liao L; Hilsenbeck SG; Brown PH; Xu J; Lee AV
BMC Cancer; 2011 Aug; 11():377. PubMed ID: 21867536
[TBL] [Abstract][Full Text] [Related]
13. The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis.
Wellberg EA; Johnson S; Finlay-Schultz J; Lewis AS; Terrell KL; Sartorius CA; Abel ED; Muller WJ; Anderson SM
Breast Cancer Res; 2016 Dec; 18(1):131. PubMed ID: 27998284
[TBL] [Abstract][Full Text] [Related]
14. NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice.
Krane IM; Leder P
Oncogene; 1996 Apr; 12(8):1781-8. PubMed ID: 8622899
[TBL] [Abstract][Full Text] [Related]
15. Dual role of AP-2gamma in ErbB-2-induced mammary tumorigenesis.
Jäger R; Friedrichs N; Heim I; Büttner R; Schorle H
Breast Cancer Res Treat; 2005 Apr; 90(3):273-80. PubMed ID: 15830141
[TBL] [Abstract][Full Text] [Related]
16. Acetylshikonin isolated from Lithospermum erythrorhizon roots inhibits dihydrofolate reductase and hampers autochthonous mammary carcinogenesis in Δ16HER2 transgenic mice.
Wang J; Iannarelli R; Pucciarelli S; Laudadio E; Galeazzi R; Giangrossi M; Falconi M; Cui L; Navia AM; Buccioni M; Marucci G; Tomassoni D; Serini L; Sut S; Maggi F; Dall'Acqua S; Marchini C; Amici A
Pharmacol Res; 2020 Nov; 161():105123. PubMed ID: 32822867
[TBL] [Abstract][Full Text] [Related]
17. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.
Landis MD; Seachrist DD; Abdul-Karim FW; Keri RA
Oncogene; 2006 Jun; 25(23):3325-34. PubMed ID: 16434967
[TBL] [Abstract][Full Text] [Related]
18. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
19. HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice.
Finkle D; Quan ZR; Asghari V; Kloss J; Ghaboosi N; Mai E; Wong WL; Hollingshead P; Schwall R; Koeppen H; Erickson S
Clin Cancer Res; 2004 Apr; 10(7):2499-511. PubMed ID: 15073130
[TBL] [Abstract][Full Text] [Related]
20. Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.
Peng M; Ball-Kell SM; Tyner AL
Cell Death Dis; 2015 Aug; 6(8):e1848. PubMed ID: 26247733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
